Follow the Pundits
Tag: StocksToWatch
Biotech Hedge Fund Extraordinaire Baker Bros. Advisors LP Adds To Its Stake in Madrigal Pharmaceuticals (MDGL): Should You Buy?
When the Baker Bros. — biotech’s most famous hedge fund — start scooping up more shares of Madrigal Pharma (MDGL), you know something’s cooking. With Rezdiffra sales booming, losses shrinking, and Wall Street titans circling, the tune of this Madrigal might be worth humming 🎶.
Bill Ackman’s Pershing Square Still Noshes on Restaurant Brands International (QSR). Should You?
Restaurant Brands International ($QSR) is cooking up dividends, international growth, and a massive Burger King reset. Bill Ackman’s Pershing Square still owns a super-sized stake—should you follow suit, or wait for a dip before ordering?
Bill Ackman’s Pershing Square Still Hearts Brookfield (BN)
Bill Ackman still loves Brookfield, his top Pershing Square bet—now up 39%! But at nearly $68 per share, has the value vanished? We dig into insider buying, institutional interest, financial highlights, and whether this former bargain is still a buy. 💼📈
GAMCO Investors Is Full of Winners — Except Paramount (PARA): Why This One Dud Might Finally Shine
Is Paramount Global a value trap—or a future media giant in disguise? Streaming growth, big-name backers like GAMCO and Vanguard, and Apple buyout rumors make this drama worth watching. 🍿🎥
Baker Bros. Advisors Just Added to Kymera. Should You Buy the Stock?
Baker Bros. just dropped $28.8M on Kymera Therapeutics. Insane confidence or brilliant foresight? We decode the science, strategy, and stats—including $775M cash, STAT6 breakthroughs, and the risk baked into that juicy pipeline. Should you take a nibble?
Bausch Health: Paulson Doubles Down, Stock Breaks Out, Recovery Accelerates
Bausch Health ($BHC) is back in the spotlight as legendary investor John Paulson adds millions more in shares, fueling a breakout rally. With Q2 earnings showing revenue growth, profit rebound, and debt repayment plans, could BHC be staging its long-awaited comeback?